Current version snapshot

FDA-approved↗↗Metabolic↗

Current · version 4: Dulaglutide↗

Related names recorded in this version: Trulicity↗

A GLP-1 receptor agonist approved by FDA as Trulicity for blood-sugar control in type 2 diabetes and to lower cardiovascular risk in certain adults with type 2 diabetes.↗↗

This immutable URL preserves the current public version.
The canonical profile remains the primary reading view. Read the canonical profile.
Update · November 14, 2026

We added a plain-language reader guide with cited answers, re-checked the Trulicity label, and added the Drugs@FDA approval record. 12

What this version reported

Large randomized trials described in the label support its uses, including a cardiovascular outcomes trial of 9,901 adults. The label carries a boxed warning about thyroid C-cell tumors in rats.↗

Organizations named in cited records:
  • U.S. National Library of Medicine↗
  • U.S. Food and Drug Administration↗

Reader guide in this version

Key takeaway

Dulaglutide is a lab-made version of GLP-1, a gut hormone involved in blood-sugar control, and is the active ingredient in Eli Lilly’s Trulicity.1,2 It is FDA-approved to improve blood-sugar control in adults and children aged 10 and older with type 2 diabetes, and to lower the risk of major cardiovascular events in adults with type 2 diabetes and heart disease or several cardiovascular risk factors.1 The cardiovascular use rests on a randomized trial of 9,901 adults described in the label, in which a first major cardiovascular event occurred in 12.0% of the dulaglutide group and 13.4% of the placebo group.1 The label carries a boxed warning about thyroid C-cell tumors seen in rats.1

At a glance

What it is
A GLP-1 receptor agonist. The label states that dulaglutide has 90% amino acid sequence similarity to human GLP-1.1
FDA status
FDA-approved. Drugs@FDA lists Trulicity with an original approval date of September 18, 2014. The label carries a boxed warning about thyroid C-cell tumors in rats.1,2
Human evidence
Large randomized trials described in the label, including a cardiovascular outcomes trial and blood-sugar trials in adults and children.1
Evidence strength
Large randomized human trials

What is dulaglutide?

Dulaglutide is a lab-made protein that mimics GLP-1, a hormone released by the gut after eating. The label states that it has 90% amino acid sequence similarity to human GLP-1.1

In the United States it is the active ingredient of Trulicity, from Eli Lilly, according to Drugs@FDA.2

How does dulaglutide work?

The label states that dulaglutide activates the GLP-1 receptor on insulin-producing cells in the pancreas, which increases insulin release when blood sugar is high.1

The label also states that it lowers glucagon release and slows stomach emptying.1

What do human studies show?

In the REWIND trial described in the label, 9,901 adults aged 50 or older with type 2 diabetes and either established cardiovascular disease or multiple risk factors were randomized to dulaglutide or placebo alongside standard care.1

Over a median of 5.4 years, a first cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 12.0% of the dulaglutide group and 13.4% of the placebo group, a hazard ratio of 0.88, according to the label.1

The label also describes randomized blood-sugar trials in adults, including trials in people with moderate to severe kidney disease, and a 26-week placebo-controlled trial in 154 children aged 10 and older.1

What the evidence base contains

  • Large randomized human trial REWIND (NCT01394952): a randomized, double-blind, placebo-controlled cardiovascular outcomes trial in 9,901 adults with type 2 diabetes and established cardiovascular disease or multiple risk factors, with a median follow-up of 5.4 years.1
  • Large randomized human trial A 26-week randomized, double-blind trial in 807 adults with type 2 diabetes that compared dulaglutide with metformin, one of several blood-sugar trials in the label.1
  • Controlled human trial A 26-week randomized, double-blind, placebo-controlled trial (NCT02963766) in 154 children aged 10 and older with type 2 diabetes.1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is dulaglutide FDA-approved?

Yes. Drugs@FDA lists Trulicity, application BLA125469, with an original approval date of September 18, 2014.2

The Trulicity label cited here (DailyMed SPL version 62, published August 10, 2026) states that it is indicated, with diet and exercise, to improve blood-sugar control in adults and children aged 10 and older with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.1

The label carries a boxed warning: dulaglutide caused thyroid C-cell tumors in rats, and it is unknown whether it causes such tumors, including medullary thyroid carcinoma, in humans. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.1

Other warnings in the label cover acute pancreatitis, low blood sugar when combined with insulin or insulin secretagogues, allergic reactions, kidney injury from fluid loss, severe gastrointestinal reactions, diabetic eye complications, gallbladder disease and aspiration during anesthesia or deep sedation.1

Timeline

  1. FDA approves Trulicity, according to Drugs@FDA.2
  2. DailyMed publishes the Trulicity label version cited on this page.1

What is still unknown?

Whether dulaglutide causes thyroid C-cell tumors in humans, which the label says has not been determined.1

Whether the cardiovascular result applies beyond the trial population: REWIND enrolled adults aged 50 or older with type 2 diabetes.1

Its effects in people without type 2 diabetes: the label’s trials enrolled people with the condition.1

Sources for this version

  1. 1
    TRULICITY (dulaglutide) injection, solution · SPL version 62 · published 2026-08-10 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026

  2. 2
    Drugs@FDA application BLA125469 · original submission status AP · 2014-09-18 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026